HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Diamandopoulos, G. Th. Articles by McLane, M.-F. Search for Related Content PubMed Articles by Diamandopoulos, G. Th. Articles by McLane, M.-F.

Development of Antibodies to Viral and Tumor Antigens before Tumor Induction in Syrian Golden Hamsters Inoculated Intravenously at 3 Weeks of Age with SV40¹

Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115

Abstract

Three-week-old weanling male Syrian golden hamsters were inoculated i.v. with 10^8.5 TCID₅₀ of oncogenic DNA simian virus 40 (SV40). All input virus was cleared from the blood stream within 48 hr. Antibody to SV40 V (virion) antigen appeared as early as the 1st postinoculation week, reached a peak by the 3rd week, and gradually decreased thereafter. Antibody to SV40 T (tumor) antigen was first detected by the 4th week. Its appearance preceded tumor induction by as many as 6 weeks for a tumor at the in situ stage, and 10 weeks for a palpable tumor. The results indicate that the development of antibody to viral and tumor antigens in hamsters inoculated i.v. at 3 weeks of age with high titer SV40 precedes rather than coincides with or follows the induction of tumors. The presence, therefore, of these antibodies in the serum of hosts in which the virus-cell interaction is of the transforming type, only signifies prior virus exposure, and can not be taken as evidence for the establishment of tumors in vivo.

Footnotes

¹ This investigation was supported by U. S. Public Health Service Research Grant CA-08731 from the National Cancer Institute, National Institutes of Health.

² Recipient of U. S. Public Health Service Research Career Development Award 5-KO4-13,444 from the National Cancer Institute, National Institutes of Health.